Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients

Abstract Objectives The purpose of this study was to examine the treatment retention and efficacy of abatacept, the first member of a new class of biologic agents, in Japanese rheumatoid arthritis (RA) patients during clinical practice. Methods A retrospective multicenter study was conducted with pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Modern rheumatology 2013-09, Vol.23 (5), p.904-912
Hauptverfasser: Takahashi, Nobunori, Kojima, Toshihisa, Terabe, Kenya, Kaneko, Atsushi, Kida, Daihei, Hirano, Yuji, Fujibayashi, Takayoshi, Yabe, Yuichiro, Takagi, Hideki, Oguchi, Takeshi, Miyake, Hiroyuki, Kato, Takefumi, Fukaya, Naoki, Ishikawa, Hisato, Hayashi, Masatoshi, Tsuboi, Seiji, Kato, Daizo, Funahashi, Koji, Matsubara, Hiroyuki, Hattori, Yosuke, Hanabayashi, Masahiro, Hirabara, Shinya, Yoshioka, Yutaka, Ishiguro, Naoki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objectives The purpose of this study was to examine the treatment retention and efficacy of abatacept, the first member of a new class of biologic agents, in Japanese rheumatoid arthritis (RA) patients during clinical practice. Methods A retrospective multicenter study was conducted with patients who underwent abatacept therapy for 24 weeks (n = 143). Results Patients at baseline had a mean age of 63.5 years, a mean disease duration of 11.3 years, and a mean disease activity score in 28 joints (DAS28) of 4.5. Overall retention of abatacept treatment was 83.2 % at 24 weeks, when 46.2 % of patients achieved DAS28-defined low disease activity (LDA; DAS28
ISSN:1439-7595
1439-7609
DOI:10.3109/s10165-012-0760-4